The U.K.’s National Institute of Health and Care Excellence has recommended funding for Iluvien as treatment for noninfectious posterior uveitis, Alimera announced.
With this recommendation, the U.K.’s National Health Service will pay for prescriptions for the fluocinolone acetonide intravitreal implant 0.19 mg treatment of noninfectious uveitis affecting the posterior segment, according to the company press release.
Iluvien is also indicated for and funded for the treatment of diabetic macular edema in the U.K.
“We continue to execute on our plans to launch Iluvien’s new indication in Europe for noninfectious posterior uveitis, a significant and, we believe, poorly served medical need. The positive funding recommendation from NICE facilitates patient access in England and Wales for this second indication with funding from the NHS,” said Rick Eiswirth, president and CEO of Alimera Sciences.
The Iluvien sustained release implant is designed to release submicrogram levels of fluocinolone acetonide for 36 months.